SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Group")
Timing of FY results announcement
4 December 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, confirms that, due to the logistics of the auditors sign-off, there will be a short delay in the publication of the FY results. The Directors anticipate that the signing-off of the accounts and in turn, the issue of the FY Results announcement, will happen later today.
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO
|
+44 (0) 191 495 7325 |
| Cavendish Capital Markets Limited Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)
| +44 (0) 20 7397 8900 |
| Vigo Consulting (financial press) Rozi Morris | +44 (0) 20 7390 0231 +44 (0) 7740 859 962 |
|
| |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plcand the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:www.skinbiotherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
